Michael Amoroso Sells 36,838 Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) CEO Michael Amoroso sold 36,838 shares of the business’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $4.67, for a total value of $172,033.46. Following the transaction, the chief executive officer now directly owns 107,087 shares in the company, valued at $500,096.29. This trade represents a 25.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Michael Amoroso also recently made the following trade(s):

• On Monday, November 4th, Michael Amoroso sold 3,012 shares of Precision BioSciences stock. The shares were sold at an average price of $8.19, for a total transaction of $24,668.28.

Precision BioSciences Trading Up 9.0 %

Precision BioSciences stock traded up $0.41 during trading on Wednesday, hitting $4.97. The company had a trading volume of 269,389 shares, compared to its average volume of 1,803,615. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.34. The company’s 50 day simple moving average is $5.62 and its 200-day simple moving average is $8.04. Precision BioSciences, Inc. has a 1-year low of $3.61 and a 1-year high of $19.43. The stock has a market cap of $38.12 million, a price-to-earnings ratio of 82.85 and a beta of 1.51.

Institutional Investors Weigh In On Precision BioSciences

A hedge fund recently raised its stake in Precision BioSciences stock. Geode Capital Management LLC grew its holdings in Precision BioSciences, Inc. (NASDAQ:DTIL) by 40.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 65,974 shares of the company’s stock after acquiring an additional 19,088 shares during the period. Geode Capital Management LLC owned about 0.86% of Precision BioSciences worth $591,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 37.99% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on DTIL shares. HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Precision BioSciences in a research report on Friday, January 10th. BMO Capital Markets raised Precision BioSciences from a “market perform” rating to an “outperform” rating and set a $34.00 price objective for the company in a research report on Friday, January 10th.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.